Moderna, Inc. Common Stock vs. Protara Therapeutics, Inc. Common Stock
MRNA
Moderna, Inc. Common Stock
$143.30 +3.85%
VS TARAProtara Therapeutics, Inc. Common Stock
$3.85 +0.92%
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| MRNA | TARA | |
|---|---|---|
| Market Cap | $55.09 billion | $225.74 million |
| Revenue (TTM) | $2.23 billion | $3.14 million |
| Net Income (TTM) | $-3,151,000,000 | $-70,015,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| MRNA | TARA | |
|---|---|---|
| Price / Book | 8.15 | 1.40 |
| Price / Sales | 24.73 | 71.98 |
MRNA and TARA split the valuation factors evenly.
Profitability
| MRNA | TARA | |
|---|---|---|
| Net Margin | -141.43% | -2232.62% |
| Return on Equity | -46.61% | -43.40% |
MRNA and TARA split the profitability factors evenly.
Risk & Sentiment
| MRNA | TARA | |
|---|---|---|
| Short Interest | 0.01% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: MRNA overview, MRNA financials, TARA overview, TARA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.